A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Summary

Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.

Timeline

Start

2022-09-30

Primary completion

2024-01-31

Completion

2024-06-13

Outcome

Met primary endpoint

registry analysis (other test); Placebo vs Fremanezumab Monthly/Quarterly; p <0.0001; LS Mean Difference -1.8 (95% CI -2.66 to -0.95); ANCOVA NCT05458011 ↗

Drugs

Indications